AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7778529 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg twice daily
Number of subjects: 101
Study 7778529 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 15 mg twice daily
Number of subjects: 101
Study 7778529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 2306782 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F catheters
Number of subjects: 52
Study 2306782 — intervention group
Group type: COMPARATOR
Intervention: 7/8F catheters
Number of subjects: 52
Study 312976 — intervention group
Group type: EXPERIMENTAL
Intervention: Solu‐Medrol (methylprednisolone sodium succinate) 1 g/liter
Number of subjects: 20
Study 312976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 20
Study 312976 — intervention group
Group type: EXPERIMENTAL
Intervention: Solu‐Medrol (methylprednisolone sodium succinate)
Number of subjects: 20
Study 31573835 — intervention group
Group type: EXPERIMENTAL
Intervention: CMM+KneeKG
Number of subjects: 515
Study 31573835 — intervention group
Group type: EXPERIMENTAL
Intervention: CMM+KneeKG+Education
Number of subjects: 515
Study 31573835 — intervention group
Group type: COMPARATOR
Intervention: CMM
Number of subjects: 515
Study 31748254 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and infant home nurse visit (NV)
Number of subjects: 742
Study 31748254 — intervention group
Group type: COMPARATOR
Intervention: Control (free transportation for prenatal care plus child development screening and referral)
Number of subjects: 742
Study 28134057 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL + LPV/r
Number of subjects: 50
Study 28134057 — intervention group
Group type: COMPARATOR
Intervention: EFV/TDF/FTC
Number of subjects: 50
Study 25887067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3861
Study 25887067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3861
Study 24583364 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic lumbar discectomy (PELD)
Number of subjects: 0
Study 24583364 — intervention group
Group type: COMPARATOR
Intervention: Traditional open lumbar discectomy (OD)
Number of subjects: 0
Study 24333889 — intervention group
Group type: EXPERIMENTAL
Intervention: Three months of drug therapy for comorbid mental disorders
Number of subjects: 55
Study 19631848 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics
Number of subjects: 0
Study 17474852 — intervention group
Group type: EXPERIMENTAL
Intervention: Active navigation
Number of subjects: 54
Study 17474852 — intervention group
Group type: COMPARATOR
Intervention: Passive navigation
Number of subjects: 54
Study 15059786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic hyperventilation (IH)
Number of subjects: 39
Study 15059786 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 39
Study 11851661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensopress bandages
Number of subjects: 112
Study 11851661 — intervention group
Group type: COMPARATOR
Intervention: Elastocrepe bandages
Number of subjects: 112
Study 10401950 — intervention group
Group type: EXPERIMENTAL
Intervention: CHDF circuit with a haemofilter made of polymethylmethacrylate membrane primed with 50 mg nafamostat in 500 ml saline, continuous injection of 0.5 mg/kg per h nafamostat, 700 ml/h of dialysis fluid and 1000 ml/h of filtrate fluid
Number of subjects: 10
Study 7641525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataphoric devices (spoken stress and the indefinite this)
Number of subjects: 0
Study 2620043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine (135 mg, two capsules, three times daily)
Number of subjects: 64
Study 2620043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (250 mg, two capsules, three times daily)
Number of subjects: 64
Study 2620043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules, three times daily)
Number of subjects: 64
Study 1091532 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (20 g daily)
Number of subjects: 20
Study 1091532 — intervention group
Group type: COMPARATOR
Intervention: Ground oatflakes (equal volume)
Number of subjects: 20
Study 31021882 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus plane block (SPB) with 25 ml of ropivacaine 0.5%
Number of subjects: 72
Study 31021882 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 72
Study 28276061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral pain self‐management (CBPSM) protocol delivered by physical therapists (PTs)
Number of subjects: 588
Study 28276061 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 588
Study 25478975 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.75 μg/kg over 30 seconds)
Number of subjects: 54
Study 25478975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg over 30 seconds)
Number of subjects: 54
Study 25478975 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg over 30 seconds)
Number of subjects: 54
Study 23228271 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 60
Study 23228271 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm vertical
Number of subjects: 60
Study 23228271 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil Plus
Number of subjects: 60
Study 21516005 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-foot reflexology (1 hr/session, 3 times a week for 6 weeks)
Number of subjects: 60
Study 21516005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study 19483370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable tablets (10 g/trial)
Number of subjects: 7
Study 19483370 — intervention group
Group type: COMPARATOR
Intervention: Control tablets (10 g/trial)
Number of subjects: 7
Study 16512765 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - quadrant root planing at 1-week intervals over four consecutive sessions
Number of subjects: 45
Study 16512765 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal debridement plus povidone-iodine group (PD-PIG) - 45-minute full-mouth debridement with ultrasonic instrument and 0.5% povidone-iodine irrigation
Number of subjects: 45
Study 16512765 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal debridement group (PDG) - 45-minute full-mouth debridement with ultrasonic instrument and NaCl irrigation
Number of subjects: 45
Study 15330904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 419
Study 15330904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no sedation)
Number of subjects: 419
Study 11761819 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ambroxol
Number of subjects: 30
Study 11761819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9099565 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced comfort levels (C)
Number of subjects: 10
Study 9099565 — intervention group
Group type: COMPARATOR
Intervention: Unbalanced comfort levels (C)
Number of subjects: 10
Study 9099565 — intervention group
Group type: COMPARATOR
Intervention: Unbalanced comfort levels (C) with halved unbalancing
Number of subjects: 10
Study 9099565 — intervention group
Group type: COMPARATOR
Intervention: Unbalanced comfort levels (C) with doubled unbalancing
Number of subjects: 10
Study 9099565 — intervention group
Group type: COMPARATOR
Intervention: 20% unbalancing
Number of subjects: 10
Study 8131253 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg mefloquine
Number of subjects: 110
Study 8131253 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg mefloquine
Number of subjects: 110
Study 8131253 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (30 mg.kg‐1.day‐1) + Tetracycline (25 mg.kg‐1.day‐1) for re-treatment
Number of subjects: 110
Study 2481671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific agents not detailed)
Number of subjects: 0
Study 2481671 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent regimens
Number of subjects: 0
Study 2481671 — intervention group
Group type: EXPERIMENTAL
Intervention: New approaches to management
Number of subjects: 0
Study 31351696 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-view radiograph series (AP pelvis and Dunn hip)
Number of subjects: 0
Study 31351696 — intervention group
Group type: COMPARATOR
Intervention: 5-view radiograph series (AP pelvis, AP, 45° Dunn, frog lateral, false profile)
Number of subjects: 0
Study 31707838 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' recommendation for surgery
Number of subjects: 194
Study 31707838 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' recommendation for physiotherapy
Number of subjects: 194
Study 31707838 — intervention group
Group type: COMPARATOR
Intervention: No recommendation
Number of subjects: 194
Study 31648764 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided strategy
Number of subjects: 2492
Study 31648764 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided strategy
Number of subjects: 2492
Study 31648764 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean FFR value
Number of subjects: 2492
Study 31648764 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean iFR value
Number of subjects: 2492
Study 29046732 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1): 300 g of vegetables and legumes containing on average 191 μg/day of folate and 1 hazelnut oil capsule
Number of subjects: 40
Study 29046732 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (G2): 300 g of vegetables and legumes containing on average 191 μg/day of folate and 1 placebo capsule
Number of subjects: 40
Study 29046732 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (G3): 300 g of vegetables and legumes containing on average 90 μg/day of folate and 1 hazelnut oil capsule
Number of subjects: 40
Study 29046732 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (G4): Follow-up with regular dietary habits
Number of subjects: 40
Study 27097492 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion of low molecular dextran via the splenic artery
Number of subjects: 92
Study 27097492 — intervention group
Group type: COMPARATOR
Intervention: Control group (extensive devascularization around the cardia)
Number of subjects: 92
Study 25305223 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (10 mg/day)
Number of subjects: 29
Study 25305223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22094154 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal bearing
Number of subjects: 80
Study 22094154 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-ceramic bearing
Number of subjects: 80
Study 19689091 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive deviance approach (PD Micah)
Number of subjects: 371
Study 19689091 — intervention group
Group type: COMPARATOR
Intervention: Micah (control group)
Number of subjects: 371
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 5 microg
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 25 microg
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 50 microg
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 75 microg
Number of subjects: 100
Study 16797805 — intervention group
Group type: COMPARATOR
Intervention: AVA
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 5 microg (after 3rd vaccination)
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 25 microg (after 3rd vaccination)
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 50 microg (after 3rd vaccination)
Number of subjects: 100
Study 16797805 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA102 75 microg (after 3rd vaccination)
Number of subjects: 100
Study 12622768 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-starch-based gluten-free diet
Number of subjects: 57
Study 12622768 — intervention group
Group type: COMPARATOR
Intervention: Natural gluten-free diet
Number of subjects: 57
Study 10660924 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology (30 minutes total by a certified reflexologist)
Number of subjects: 23
Study 10660924 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 23
Study 9291263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by two implants with ball attachments
Number of subjects: 110
Study 9291263 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implants with an interconnecting bar
Number of subjects: 110
Study 9291263 — intervention group
Group type: EXPERIMENTAL
Intervention: Four interconnected implants
Number of subjects: 110
Study 8346830 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (0.5, 1.0, 1.5, or 2.0 mg/kg)
Number of subjects: 208
Study 8346830 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (2 mg/kg)
Number of subjects: 208
Study 8346830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 2953734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 60
Study 2953734 — intervention group
Group type: COMPARATOR
Intervention: Sodium-meglumine diatrizoate (Renografin-76)
Number of subjects: 60
Study 31620802 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks for 12 weeks, then 80 mg open-label ixekizumab every 4 weeks through Week 52
Number of subjects: 0
Study 31620802 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks, then 80 mg open-label ixekizumab every 4 weeks through Week 52
Number of subjects: 0
Study 30041702 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of co-amoxiclav
Number of subjects: 3424
Study 30041702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3424
Study 28522085 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified uvulopalatopharyngoplasty (UPPP)
Number of subjects: 65
Study 28522085 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed surgery)
Number of subjects: 65
Study 26265075 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Resistance Training (ERT) twice a week for 8 weeks
Number of subjects: 40
Study 26265075 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 40
Study 23294528 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum YKL-40
Number of subjects: 4372
Study 21410627 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin FDC 50/500 mg bid
Number of subjects: 1250
Study 21410627 — intervention group
Group type: COMPARATOR
Intervention: metformin monotherapy 500 mg bid (uptitrated to 1000 mg bid)
Number of subjects: 1250
Study 21410627 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin FDC
Number of subjects: 1250
Study 21410627 — intervention group
Group type: COMPARATOR
Intervention: metformin monotherapy
Number of subjects: 1250
Study 18242449 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (sodium chondroitin sulfate 4%-sodium hyaluronate 3%)
Number of subjects: 30
Study 18242449 — intervention group
Group type: COMPARATOR
Intervention: DuoVisc (Viscoat and Provisc [sodium hyaluronate 1%])
Number of subjects: 30
Study 16532455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin treatment (600-2,700 mg/day)
Number of subjects: 6
Study 16532455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin treatment
Number of subjects: 6
Study 16532455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 14612979 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg beta-carotene or lycopene supplementation
Number of subjects: 30
Study 14612979 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene or lycopene supplementation
Number of subjects: 30
Study 14612979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10843171 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 543
Study 10843171 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day
Number of subjects: 543
Study 10843171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study 8869876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy
Number of subjects: 875
Study 8869876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 1346817 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (to achieve an activated partial thromboplastin time of 1.5 to 2.0 times the pretreatment value)
Number of subjects: 170
Study 1346817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (adjusted only for body weight) for 10 days
Number of subjects: 170
Study 1346817 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 170
Study 1346817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 170
Study 6845106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 5.0 micrograms/h
Number of subjects: 9
Study 6845106 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 2.5 micrograms/h
Number of subjects: 9
Study 6845106 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study 31761744 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone information (experimental group)
Number of subjects: 160
Study 31761744 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face information (control group)
Number of subjects: 160
Study 30275142 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDAS e‐learning (G1, n=21)
Number of subjects: 64
Study 30275142 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDAS e‐learning + digital learning tool (DLT) (G2, n=22)
Number of subjects: 64
Study 30275142 — intervention group
Group type: COMPARATOR
Intervention: No training (control group, G3, n=21)
Number of subjects: 64
Study 27553712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU) administered intranasally
Number of subjects: 38
Study 27553712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24471659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 111
Study 24471659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg then oral celecoxib 400 mg at 12 hours (group PC)
Number of subjects: 111
Study 24471659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 2 g then oral 1 g six-hourly (group PA)
Number of subjects: 111
Study 24471659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous parecoxib, oral celecoxib, and paracetamol (group PCPA)
Number of subjects: 111
Study 22752297 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1,000 mg orally once daily + prednisone 5 mg orally twice daily
Number of subjects: 33
Study 22752297 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA)
Number of subjects: 33
Study 19056215 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 139
Study 19056215 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage for 24 hours
Number of subjects: 139
Study 19056215 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage for 48 hours
Number of subjects: 139
Study 17676319 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day
Number of subjects: 12
Study 17676319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg on the first day and 200 mg on the second day
Number of subjects: 12
Study 16231818 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopy (260 patients)
Number of subjects: 522
Study 16231818 — intervention group
Group type: COMPARATOR
Intervention: Active observation (262 patients)
Number of subjects: 522
Study 12135535 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/d venlafaxine
Number of subjects: 146
Study 12135535 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/d fluoxetine
Number of subjects: 146
Study 10197842 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 297
Study 8845580 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine-relevant cold-pressor test
Number of subjects: 121
Study 8845580 — intervention group
Group type: EXPERIMENTAL
Intervention: Masculine-relevant cold-pressor test
Number of subjects: 121
Study 2332919 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride (360 mg daily)
Number of subjects: 52
Study 2332919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride (240 mg daily)
Number of subjects: 52
Study 2332919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6774359 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH), 0.5 mg i.v.
Number of subjects: 20
Study 6774359 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormones (TH) pretreatment
Number of subjects: 20
Study 6774359 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) with TH pretreatment
Number of subjects: 20
Study 31405122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri CP2305 tablets
Number of subjects: 60
Study 31405122 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 60
Study 28625442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6μg·kg‐1) followed by 0.2μg·kg‐1·h‐1 until the end of operation
Number of subjects: 72
Study 28625442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 72
Study 25888548 — intervention group
Group type: EXPERIMENTAL
Intervention: 65Gy boost + chemoradiation (sCRT)
Number of subjects: 120
Study 25888548 — intervention group
Group type: COMPARATOR
Intervention: 50Gy standard chemoradiation (sCRT)
Number of subjects: 120
Study 23648611 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 46